GenPath logo in conjunction with oncology

SOLID TUMORS

Minimum tumor input requirement: 0.65mm3 tumor tissue volume, showing at least 10% tumor cellularity. Metastatic tumor tissue is preferred; tumor tissue from primary site of origin is also acceptable in patients with advanced stage disease.

Slides

10–15 unstained slides. Minimum of 0.65mm3 cut at 5 microns thickness containing adequate amounts of tumor to be analyzed with corresponding H&E slide, and a pathology report.

FFPE

Specimen block preferred.

Shavings

If tumor nuclei in sample is >50%, 6 to 9 rolls cut at 10 microns and placed in a 1.5ml tube. Samples must come with corresponding H&E slides from the top and bottom of the sample, and a pathology report.

DNA

Previously extracted DNA is acceptable. Minimum 20ng is required. 40ng preferred.

Cytology smears are also acceptable.

HEMATOLOGY

For chronic lymphoid leukemias, Peripheral blood or marrow aspirate liquid samples may be submitted in Lavender top EDTA or Green Top Sodium Heparinized tubes.

  • 10-15 ml preferred, although a testing will be attempted with as little as 0.5 ml.

For tissue based lymphomas, FFPE biopsy specimens (needle core or excisional biopsies) are acceptable, and same considerations as for solid tumors would apply.

Slides

10–15 unstained slides. Minimum of 0.65mm3 cut at 5 microns thickness containing adequate amounts of tumor to be analyzed with corresponding H&E slide, and a pathology report.

FFPE

Specimen block preferred.

Shavings

If tumor nuclei in sample is >50%, 6 to 9 rolls cut at 10 microns and placed in a 1.5ml tube. Samples must come with corresponding H&E slides from the top and bottom of the sample, and a pathology report.

DNA

Previously extracted DNA is acceptable. Minimum 20ng is required. 40ng preferred.

Cytology smears are also acceptable. Lightly decalcified bone marrow core biopsies may also be considered.